Lipocine (STU:2VT0) Current Accrued Expense: €0.93 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2VT0 Lipocine Inc STU:2VT0
49 GF Score
Price €3.94
GF Value €2.49
! 4 Warning Signs
View Full Analysis

What is Lipocine Current Accrued Expense?

Lipocine STU:2VT0 49 Current Accrued Expense is €0.93 Mil as of Jun. 2026. GuruFocus rates STU:2VT0 with a GF Score™ of 49/100 and a GF Value™ of €2.49. The stock has 4 warning signs investors should review.

Lipocine's Current Accrued Expense for the quarter that ended in Jun. 2026 was €0.93 Mil.

Lipocine's quarterly Current Accrued Expense declined from Dec. 2025 (€1.06 Mil) to Mar. 2026 (€0.56 Mil) but then increased from Mar. 2026 (€0.56 Mil) to Jun. 2026 (€0.93 Mil).

Lipocine's annual Current Accrued Expense declined from Dec. 2023 (€1.12 Mil) to Dec. 2024 (€0.88 Mil) but then increased from Dec. 2024 (€0.88 Mil) to Dec. 2025 (€1.06 Mil).

Lipocine Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Lipocine's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipocine Current Accrued Expense Chart

Lipocine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 1.02 1.12 0.88 1.06

Lipocine Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.64 1.06 0.56 0.93
STU:2VT0
49GF Score
Lipocine Inc STU:2VT0
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lipocine Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €0.93 Mil mean?
Lipocine (STU:2VT0) has a Current Accrued Expense of €0.93 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Lipocine and its competitors.
Is Lipocine's Current Accrued Expense too high?
Lipocine's current Current Accrued Expense is €0.93 Mil. Overall, Lipocine has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Lipocine's Current Accrued Expense compare to NXTC and VYNE?
Lipocine's Current Accrued Expense of €0.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Lipocine and its competitors. Lipocine's current Current Accrued Expense is €0.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Lipocine (STU:2VT0) has a current Current Accrued Expense of €0.93 Mil. The stock's GF Value™ is €2.49, compared to a current price of €3.94 — trading 58.4% above its estimated fair value. The current Current Accrued Expense is €0.93 Mil. Lipocine's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Lipocine (STU:2VT0), the current Current Accrued Expense is €0.93 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lipocine (STU:2VT0) Overvalued in 2026?

Based on GuruFocus' analysis, Lipocine stock appears to be overvalued. The current stock price of €3.94 is trading 58.4% above its estimated GF Value™ of €2.49.

Key valuation signals for STU:2VT0:

  • Current Accrued Expense: €0.93 Mil
  • GF Value™: €2.49 vs. price of €3.94 (58.4% above fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the STU:2VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lipocine Business Description

Other Exchanges LPCN:USA
Address 675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
49GF Score

Get the complete analysis for STU:2VT0

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.94
Price
€2.49
GF Value